Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Artgen reported for 9 months of 2024 by RAS

11/1/24 ABIO

Board of Directors of Sebcement recommended dividends

11/1/24 SKCM

LLC KVLZ Kristall reported for 9 months of 2024

11/1/24 KLVZ

Arsagera reported for 9 months of 2024 by RAS

11/1/24 ARSA

YTEK reported for 9 months of 2024 by RAS

11/1/24 YAKG

Novatek reports for 9 months of 2024 by RAS

11/1/24 NVTK

Board of Directors of Europlan recommended dividends

11/1/24 LEAS

IVA Technologies revenue grew by 52% in 9 months

11/1/24 IVAT

Pharmsintez reported for 9 months of 2024 by RAS

10/31/24 LIFE

EL5-Energo reported for 9 months of 2024 by IFRS

10/31/24 ELFV